Mehnert JM, Mitchell T, Huang AC, Aleman TS, et al. BAMM (BRAF Autophagy and MEK inhibition in Melanoma): A phase I/II trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600-mutant melanoma. Clin Cancer Res 2022 Jan 12. pii: 1078-0432.CCR-21-3382.
PMID: 35022320